Technology fronts

Scans that show brain structure and, in selected people, amyloid or other biology.

Spinal-fluid and blood tests that can support an Alzheimer’s biology question.

Genes can change risk and, rarely, cause familial disease. ApoE ε4 also changes antibody-safety counselling.

Medicines and non-drug support aimed at symptoms, not at reversing the disease.

Antibodies that lower amyloid plaques in early symptomatic Alzheimer’s disease, with ARIA monitoring.

Tau is the tangle protein. Treatments that lower or block tau remain investigational.

Immune activity in the brain is a research front, not a licensed dementia cure.

Hearing, blood pressure, smoking, sleep, and movement are part of brain-health care. They are not a substitute for diagnosis.

Apps and remote tests can track change. They do not diagnose dementia on their own.

Software can help read scans or organise notes. It is not a clinician and it is not a diagnosis.

Who coordinates care, how families get respite, and how clinics monitor antibodies are delivery problems, not only science problems.